

## GLOBAL IMPLEMENTATION OF PRECISION ONCOLOGY:

# WINNING THE WAR AGAINST CANCER



MONDAY JUNE 25, 2018



### Welcome and opening remarks

The 10<sup>th</sup> Anniversary of the WIN Consortium: lessons and perspectives  
*John Mendelsohn, Chairman WIN Consortium; The University of Texas MD Anderson Cancer Center (UT-MDACC), USA*

### PRESIDENTIAL SESSION 1: THE CHALLENGES OF BUILDING REAL COOPERATION TO IMPLEMENT PRECISION ONCOLOGY PROGRAMS: A LONG AND WINDING ROAD

**Chairs:** *John Mendelsohn, UT-MDACC, USA, Chairman of WIN Consortium; Jean-Charles Soria, MedImmune, USA*



**Keynote Lecture:** The TAPUR family of clinical trials: building a global data sharing platform in Precision Oncology  
*Richard L. Schilsky, American Society of Clinical Oncology (ASCO®), USA*



**Making Cancer History all together**  
*Stephen M. Hahn, The University of Texas MD Anderson Cancer Center, USA*



**U.S. National Cancer Institute perspective on Precision Oncology**  
*James H. Doroshow, National Cancer Institute (NCI), USA*



**Beyond standard of care: the next steps of Precision Oncology - an ESMO perspective**  
*Josep Taberero, Vall d'Hebron Institute of Oncology (VHIO), Spain. President European Society for Medical Oncology (ESMO), Switzerland*



**A view from the European Union on the international collaborations and the future of the Framework programmes**  
*Cornelius Schmalz, Head of Unit Health Research Strategy, Directorate General for Research and Innovation at the European Commission in Brussels, Belgium*

### Open Forum and Debate with the audience: The key issues of worldwide cooperation

- Technology and conceptual breakthroughs
- Industry or academic sponsored research
- Funding of clinical trials
- Publication policies

#### Moderators:

*Lisa Hutchinson, Foundation for World Health (FWH), UK, WIN Consortium*  
*Jean-Charles Soria, MedImmune, USA*

#### Panel:

*James H. Doroshow, NCI, USA*      *Cornelius Schmalz, European Commission, Belgium*  
*Stephen M. Hahn, UT-MDACC, USA*      *Josep Taberero, VHIO, Spain, ESMO*  
*John Mendelsohn, UT-MDACC, USA*  
*Richard L. Schilsky, ASCO, USA*

### SESSION 2: THE NEXT FRONTIER OF THERAPEUTICS IN NEWLY DIAGNOSED PATIENTS: STANDARD OF CARE OR MODERN BIOMARKER DRIVEN PRECISION ONCOLOGY?

**Chairs:** *Razelle Kurzrock, UCSF, USA; Josep Taberero, VHIO, Spain*



**Keynote lecture:** Preventive and curative healthcare: the next frontier for Precision Oncology  
*John Wilden, Foundation for World Health (FWH), UK*



**A new world of early diagnosis to defeat Non-Small Cell Lung Carcinoma (NSCLC)**  
 The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC  
*Amir Onn, Sheba Medical Center, Israel*



**Lessons from long-term survey of Stage I NSCLC**  
*Harvey I. Pass, New York University, NYU Langone Health, USA*



**Keynote Lecture:** Patients' expectations and hopes  
*Ellen V. Sigal, Friends of Cancer Research, USA*



**Newly diagnosed breast cancer at the frontier of precision oncology**  
*Laura Esserman, University of California San Francisco (UCSF), USA*

## ORGANIZING COMMITTEE

### CHAIRS:

*John Mendelsohn (USA)*  
*Razelle Kurzrock (USA)*

### MEMBERS:

*Lisa Hutchinson (UK)*  
*Brian Leyland-Jones (USA)*  
*Amir Onn (Israel)*  
*Richard L. Schilsky (USA)*  
*Chang-Sik Yu (South Korea)*  
*Vladimir Lazar (France)*  
*Catherine Bresson (France)*

## MONDAY JUNE 25, 2018 - CONTINUED

### Open forum and debate with the audience: **Next frontiers of therapeutics**

**Moderators:**

Razelle Kurzrock, UCSD, USA  
Josep Taberero, VHIO, Spain

**Panel:**

Laura Esserman, UCSF, USA  
Amir Onn, Sheba Medical Center, Israel  
Harvey I. Pass, NYU Langone Health, USA  
Ellen V. Sigal, Friends of Cancer Research, USA

WELCOME RECEPTION, NETWORKING AND POSTER VIEWING running at the same time as

**MEET THE PROFESSOR** sessions to choose from:

- Meeting 1:** James H. Doroshow, National Cancer Institute (NCI), USA  
Josep Taberero, Vall d'Hebron (VHIO), Spain; President (ESMO), Switzerland
- Meeting 2:** Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA  
John Mendelsohn, The University of Texas, MD Anderson Cancer Center, USA
- Meeting 3:** Ellen V. Sigal, Friends of Cancer Research, USA
- Meeting 4:** Carl H. June, Perelman School of Medicine, USA  
Laura Esserman, University of California San Francisco, USA
- Meeting 5:** Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium

## TUESDAY JUNE 26, 2018

### SESSION 3: **DISRUPTIVE CONCEPTS AND CLINICAL TRIALS SHIFTING THE PARADIGM OF PRECISION ONCOLOGY**

**Chairs:** Carl H. June, Perelman School of Medicine, USA; Richard L. Schilsky, ASCO, USA



**Keynote Lecture:** The tri-antibody methodology for blocking the cancer cells: perspectives  
Yosef Yarden, Weizmann Institute of Science, Israel



The first targeted agents tri-therapy combination trial in first therapeutic line of metastatic NSCLC: the WIN Consortium SPRING\_01 trial  
Razelle Kurzrock, University of California San Diego (UCSD), USA



The challenges of combining targeted therapies in biomarker driven Precision Oncology – a Pharma perspective  
Jean-François Martini, Pfizer Inc., USA



MY-pathway study: when biology meets the challenges of Precision Oncology  
Mary Beattie, Genentech, USA

### SESSION 4: **NEW CONCEPTS AND THERAPEUTICS AVENUES IN PRECISION ONCOLOGY**

**Chair:** Alan Spatz, McGill Segal Cancer Center, Canada



**Keynote Lecture:** Precision CAR T-cells therapeutics  
Carl H. June, Perelman School of Medicine, 2017 David A. Karnofsky Memorial Award ASCO®, USA



The systems biology approach to Precision Oncology: ready to defeat cancer  
Leroy Hood, Institute for Systems Biology (ISB), USA



Immunotherapies turning cold in hot tumors  
Jean-Charles Soria, MedImmune, USA



Precision Oncology approaches for immunotherapy  
Eric Rubin, Merck, USA

## TUESDAY JUNE 26, 2018 - CONTINUED

### Open forum and debate with the audience: **The future of drug development for Precision Oncology**

**Moderators:**

Leroy Hood, *Institute for Systems Biology, USA*  
Alan Spatz, *McGill Segal Cancer Centre, Canada*

**Panel:**

Carl H. June, *Perelman School of Medicine, USA*  
Jean-François Martini, *Pfizer Inc., USA*  
Eric Rubin, *Merck, USA*  
Richard L. Schilsky, *ASCO, USA*

### SESSION 5: **TOWARDS A NEW MODEL OF DRUG DEVELOPMENT: THE COMBINATION OF TARGETED THERAPIES**

**Chair:** *to be confirmed*



The great hits of Precision Oncology  
*Bernadette Toner, GenomeWeb, USA*



Access of patients to Precision Oncology  
*Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium*

### Roundtable and panel discussion

**Moderators:**

*To be confirmed*

**Panel:**

*Francesco De Lorenzo, ECPC, Belgium*  
*Bernadette Toner, GenomeWeb, USA*

### SESSION 6: **10<sup>th</sup> YEAR OF THE WIN SYMPOSIUM IN THE ERA OF MODERN ONCOLOGY**

**Chairs:** *Vladimir Lazar, Catherine Bresson, WIN Consortium, France*

### 2 best posters presentations and awards

### 10<sup>th</sup> ANNIVERSARY CEREMONY OF THE WIN SYMPOSIUM

**WIN AWARDS:**

- Outstanding career
- Best speaker at WIN symposia
- Best project manager
- Best principal investigator
- Best scientific contribution
- Innovation in Precision Oncology
- Friends of WIN

**10<sup>TH</sup> ANNIVERSARY EVENT**